NICE terminates yet another assessment of a cancer medicine

20 March 2019 - This time it is pembrolizumab (Keytruda). ...

Read more →

Institute for Clinical and Economic Review releases draft evidence report on esketamine for treatment-resistant depression

21 March 2019 - Public comment period now open until 17 April 2019; requests to make oral comment during public meeting ...

Read more →

NICE wants to stop saying ‘no’ – but needs pharma’s co-operation

18 March 2019 - Suggests Orkambi row has undermined confidence in NICE process. ...

Read more →

Institute for Clinical and Economic Review appoints new members to each of its three independent evidence appraisal councils

18 March 2019 - New members bring expertise in broad range of perspectives, including patient advocacy, health policy, economics, and clinical ...

Read more →

NICE celebrates its 20th anniversary

18 March 2019 - Organisation was founded in April 1999 to improve outcome for health service users ...

Read more →

Toward a strategy to involve patients in health technology assessment in Spain

14 March 2019 - The aim of this study was to develop a feasible and effective strategy to involve patients in ...

Read more →

PBAC Public Summary Documents - November 2018 meeting (rejections and deferrals)

15 March 2019 - The Public Summary Documents (first time rejections and deferrals) from the November 2018 PBAC meeting are now ...

Read more →

Institute for Clinical and Economic Review releases draft evidence report on siponimod for treating secondary progressive multiple sclerosis

14 March 2019 - Public comment period now open until 10 April 2019; requests to make oral comment during public meeting ...

Read more →

An EU wide approach to HTA: an irrelevant development or an opportunity not to be missed?

14 March 2019 - An EU-wide cooperation on HTA has been proposed recently by the European Commission, focusing on relative effectiveness ...

Read more →

Institute for Clinical and Economic Review publishes white paper on alternative models for pharmaceutical rebates

12 March 2019 - Paper explores how reforming or eliminating rebates may affect drug pricing, patient access, and incentives for future ...

Read more →

NICE u-turn backs use of Darzalex combo for myeloma relapse

12 March 2019 - Myeloma patients in England are set to gain NHS access to a new second-line treatment combination ...

Read more →

Overview of cost-effectiveness analysis

11 March 2019 - Health care decision makers, including patients, clinicians, hospitals, private health systems, and public payers (eg, Medicare), are ...

Read more →

SMC says ‘no’ to Novartis’ Kymriah for adults with lymphoma

11 March 2019 - Adults with lymphoma will not be able to access Novartis’ CAR-T therapy Kymriah on the NHS ...

Read more →

SMC - March 2019 decisions

11 March 2019 - The Scottish Medicines Consortium has today published advice accepting two new medicines. ...

Read more →

NICE nod for Almirall's Ilumetri, UCB's Cimzia

11 March 2019 - The NICE has recommended Almirall's Ilumetri and UCB's Cimzia as a treatment options for severe plaque ...

Read more →